Compare KMB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMB | INSM |
|---|---|---|
| Founded | 1910 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3B | 30.1B |
| IPO Year | 1994 | 2000 |
| Metric | KMB | INSM |
|---|---|---|
| Price | $95.37 | $139.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 24 |
| Target Price | $113.54 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 4.5M | 1.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $16,447,000,000.00 | N/A |
| Revenue This Year | $3.83 | $182.31 |
| Revenue Next Year | $3.61 | $65.19 |
| P/E Ratio | $48.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $92.42 | $63.81 |
| 52 Week High | $144.31 | $212.75 |
| Indicator | KMB | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 44.60 |
| Support Level | $92.42 | $136.24 |
| Resistance Level | $100.41 | $166.81 |
| Average True Range (ATR) | 2.10 | 4.93 |
| MACD | 0.09 | -0.86 |
| Stochastic Oscillator | 7.74 | 32.81 |
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide workplace safety and sanitation solutions. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It is slated to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.